Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Wasatch Advisors Inc.

Share on StockTwits

Wasatch Advisors Inc. trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,270,728 shares of the company’s stock after selling 290,275 shares during the quarter. Medpace makes up approximately 1.6% of Wasatch Advisors Inc.’s investment portfolio, making the stock its 12th largest position. Wasatch Advisors Inc. owned approximately 0.06% of Medpace worth $253,754,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Fuller & Thaler Asset Management Inc. raised its stake in shares of Medpace by 0.9% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 870,395 shares of the company’s stock worth $97,267,000 after buying an additional 7,741 shares during the period. Boston Trust Walden Corp raised its stake in Medpace by 3.7% in the 3rd quarter. Boston Trust Walden Corp now owns 408,284 shares of the company’s stock valued at $45,626,000 after purchasing an additional 14,749 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Medpace by 31.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 334,827 shares of the company’s stock valued at $31,146,000 after purchasing an additional 80,819 shares during the last quarter. Redwood Investments LLC raised its stake in Medpace by 43.2% in the 2nd quarter. Redwood Investments LLC now owns 220,488 shares of the company’s stock valued at $20,510,000 after purchasing an additional 66,510 shares during the last quarter. Finally, American Capital Management Inc. raised its stake in Medpace by 33.1% in the 2nd quarter. American Capital Management Inc. now owns 211,486 shares of the company’s stock valued at $19,672,000 after purchasing an additional 52,585 shares during the last quarter. 79.51% of the stock is owned by institutional investors and hedge funds.

In related news, major shareholder Medpace Investors, Llc sold 11,597 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $123.23, for a total transaction of $1,429,098.31. Following the completion of the transaction, the insider now directly owns 6,818,286 shares in the company, valued at approximately $840,217,383.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jesse J. Geiger sold 3,110 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $130.00, for a total value of $404,300.00. Following the transaction, the chief financial officer now owns 10,082 shares of the company’s stock, valued at $1,310,660. The disclosure for this sale can be found here. Insiders have sold a total of 33,610 shares of company stock valued at $4,165,272 over the last 90 days. 26.00% of the stock is currently owned by company insiders.

Several research firms recently commented on MEDP. Credit Suisse Group increased their price objective on Medpace from $92.00 to $114.00 and gave the company an “outperform” rating in a research note on Tuesday, July 28th. Truist raised Medpace from a “hold” rating to a “buy” rating and raised their target price for the stock from $124.00 to $135.00 in a research note on Friday, October 2nd. SunTrust Banks raised their target price on Medpace from $95.00 to $124.00 and gave the stock a “hold” rating in a research note on Wednesday, July 29th. Zacks Investment Research raised Medpace from a “sell” rating to a “hold” rating in a research note on Friday, October 30th. Finally, BidaskClub downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, November 17th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Medpace presently has an average rating of “Hold” and an average price target of $107.25.

Shares of NASDAQ MEDP traded up $2.47 during mid-day trading on Friday, reaching $126.43. 328,505 shares of the company’s stock were exchanged, compared to its average volume of 328,402. The firm has a market capitalization of $4.52 billion, a price-to-earnings ratio of 38.66 and a beta of 1.35. Medpace Holdings, Inc. has a 52-week low of $58.72 and a 52-week high of $144.49. The company’s 50-day moving average is $118.21 and its 200-day moving average is $107.78.

Medpace (NASDAQ:MEDP) last announced its earnings results on Saturday, October 31st. The company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. Medpace had a return on equity of 17.67% and a net margin of 13.87%. The company had revenue of $230.37 million during the quarter, compared to analysts’ expectations of $223.56 million. During the same period last year, the business posted $0.71 EPS. Medpace’s revenue for the quarter was up 6.5% on a year-over-year basis. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 4 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

See Also: How to Invest in a Bull Market

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.